As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
12 Analysts have issued a AVITA Therapeutics forecast:
12 Analysts have issued a AVITA Therapeutics forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 72 72 |
21%
21%
|
|
| Gross Profit | 61 61 |
18%
18%
|
|
| EBITDA | -39 -39 |
32%
32%
|
|
| EBIT (Operating Income) EBIT | -41 -41 |
29%
29%
|
|
| Net Profit | -49 -49 |
15%
15%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
| Head office | United States |
| CEO | James Corbett |
| Employees | 260 |
| Founded | 1992 |
| Website | www.avitamedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


